Namisol® with Alitra™ DDT - Clinical Studies

  • First In Human Trial of an Oral Tablet with Δ9-THC Namisol®; Linda E. Klumpers et al.; Eur. J. of Neurol. 17 (Supplement 3), p 493; poster presented at the EFNS congress 2010
  • THC tablet NAMISOL®: first in human PK, PD and tolerability; Linda E. Klumpers et al.; poster presented at the FIGON Dutch Medicines Days 2010
  • Two phase, repeated crossover study with dose escalation on delta-9-tetrahydrocannabinol (delta-THC) in behavioral disturbances in dementia; Geke van Elsen et al.; poster presented at the IPA congress 2011
  • First in human trial of an oral tablet with Δ9-THC (NAMISOL®); Tim L. Beumer et al.; oral presentation at the IACM conference 2011

  • Novel Δ(9)-tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects. Klumpers LE, Beumer TL, van Hasselt JG, Lipplaa A, Karger LB, Kleinloog HD, Freijer JI, de Kam ML, van Gerven JM. Br J Clin Pharmacol. Accepted manuscript online: 28 Dec 2011


Other Publications

  • Emerging treatment options for spasticity in multiple sclerosis-clinical utility of cannabinoids; John C. Ashton; Degenerative Neurological and Neuromuscular Disease 2011 (1), 15-23
  • Development of an ultra sensitive LC-MS/MS method for the simultaneous determination of Δ9-Tetrahydrocannabinol (THC) and one of its major metabolites Δ9-(11-OH) THC in human plasma; Mark Boterman et al.; poster presented at the IACM 2011